UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 657

Sortiert nach

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2018-08, Vol.36 (22), p.2251-2258

2018

Volltextzugriff (PDF)

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

The lancet respiratory medicine, 2019-05, Vol.7 (5), p.387-401

2019

Volltextzugriff (PDF)

Personalized medicine in lung cancer: what we need to know

Nature reviews. Clinical oncology, 2011-11, Vol.8 (11), p.661-668

Mok, Tony S. K

2011

Volltextzugriff (PDF)

Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations

Journal of clinical oncology, 2013-09, Vol.31 (27), p.3342-3350

2013

Volltextzugriff (PDF)

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

Journal of clinical oncology, 2011-07, Vol.29 (21), p.2866-2875

2011

Volltextzugriff (PDF)

Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2022-06, Vol.40 (17), p.1916-1928

2022

Volltextzugriff (PDF)

Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non - Small Cell Lung Cancer Patients

Clinical cancer research, 2009-03, Vol.15 (6), p.2076-2084

2009

Volltextzugriff (PDF)

Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials

JAMA oncology, 2023-04, Vol.9 (4), p.527

2023

Volltextzugriff (PDF)

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

The New England journal of medicine, 2009-09, Vol.361 (10), p.947-957

2009

Volltextzugriff (PDF)

Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status

PloS one, 2012-06, Vol.7 (6), p.e40109-e40109

2012

Volltextzugriff (PDF)

Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients

Proceedings of the National Academy of Sciences - PNAS, 2015-03, Vol.112 (11), p.E1317-E1325

2015

Volltextzugriff (PDF)

MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis

Clinical cancer research, 2016-06, Vol.22 (12), p.3048-3056

2016

Volltextzugriff (PDF)

Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab

Journal of clinical oncology, 2009-02, Vol.27 (4), p.605-611

2009

Volltextzugriff (PDF)

Population-based differences in treatment outcome following anticancer drug therapies

The lancet oncology, 2010, Vol.11 (1), p.75-84

2010

Volltextzugriff (PDF)

Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2017-10, Vol.12 (10), p.1536-1543

2017

Volltextzugriff (PDF)

EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects

Cancer treatment reviews, 2012-08, Vol.38 (5), p.416-430

2012

Volltextzugriff (PDF)

Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2009-10, Vol.27 (30), p.5080-5087

2009

Volltextzugriff (PDF)

Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference

Clinical epigenetics, 2023-03, Vol.15 (1), p.36-36, Article 36

2023

Volltextzugriff (PDF)

New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy

Journal of clinical oncology, 2009-01, Vol.27 (3), p.446-452

2009

Volltextzugriff (PDF)

Transbronchial Techniques for Lung Cancer Treatment: Where Are We Now?

Cancers, 2023-02, Vol.15 (4), p.1068

2023

Volltextzugriff (PDF)

EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas

The oncologist (Dayton, Ohio), 2012-07, Vol.17 (7), p.978-985

2012

Volltextzugriff (PDF)

Quantitative Analysis of Circulating Methylated DNA as a Biomarker for Hepatocellular Carcinoma

Clinical chemistry (Baltimore, Md.), 2008-09, Vol.54 (9), p.1528-1536

2008

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012

Journal of thoracic oncology, 2013-03, Vol.8 (3), p.373-384

2013

Volltextzugriff (PDF)

Ambient fine particulate matter inhibits 15-lipoxygenases to promote lung carcinogenesis

Journal of experimental & clinical cancer research, 2019-08, Vol.38 (1), p.359-359, Article 359

2019

Volltextzugriff (PDF)

1 – 25 von 657

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(605)
Mit Volltextzugriff
(604)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(405)
Life Sciences & Biomedicine
(389)
Humans
(332)
Oncology
(290)
Female
(167)
Male
(167)
Lung Neoplasms - Drug Therapy
(153)
Middle Aged
(149)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(128)
Aged
(126)
Adult
(115)
Lung Cancer
(115)
Lung Neoplasms - Pathology
(111)
Mutation
(110)
Lung Neoplasms - Genetics
(108)
Respiratory System
(91)
Carcinoma, Non-Small-Cell Lung - Genetics
(90)
Carcinoma, Non-Small-Cell Lung - Pathology
(83)
Tumors
(83)
Biological And Medical Sciences
(78)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

Personalized medicine in lung cancer: what we need to know

Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR -mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer

Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non - Small Cell Lung Cancer Patients

Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status

Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients

MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis

Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab

Population-based differences in treatment outcome following anticancer drug therapies

Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non–Small Cell Lung Cancer

EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects

Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference

New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy

Transbronchial Techniques for Lung Cancer Treatment: Where Are We Now?

EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas

Quantitative Analysis of Circulating Methylated DNA as a Biomarker for Hepatocellular Carcinoma

Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012

Ambient fine particulate matter inhibits 15-lipoxygenases to promote lung carcinogenesis

Suchergebnisse filtern